Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

15 oct. 2021 16h11 HE | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals completa la presentazione della domanda di variazione tipo II all'Agenzia europea per i medicinali per IMCIVREE® (setmelanotide) per le sindromi di Bardet-Biedl e Alström

BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), un'azienda biofarmaceutica in fase commerciale impegnata a cambiare radicalmente l'assistenza delle persone...
15 oct. 2021 16h11 HE | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals completa la presentación de la solicitud de variación de tipo II a la Agencia Europea del Medicamento para IMCIVREE® (setmelanotida) para los síndromes de Bardet-Biedl y Alström

BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), una empresa biofarmacéutica en fase comercial comprometida con la transformación de la atención a las personas...
15 oct. 2021 16h11 HE | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals complète la demande de variation de type II à l'Agence européenne des médicaments pour l'IMCIVREE® (setmelanotide) pour les syndromes de Bardet-Biedl et Alström

BOSTON, 15 oct. 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq : RYTM), une société biopharmaceutique au stade commercial engagée à transformer les soins des personnes atteintes de...
14 oct. 2021 16h01 HE | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMCIVREE® (setmelanotide) for Bardet-Biedl and Alström Syndromes

BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare...
14 oct. 2021 16h01 HE | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMCIVREE® (setmelanotide) for Bardet-Biedl and Alström Syndromes

BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare...
14 oct. 2021 08h00 HE | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity® Genetic Testing Program

-- New data in patients with POMC or LEPR deficiency obesity show setmelanotide led to clinically meaningful improvements in health related quality of life measures and hunger -- -- Updated results...
22 sept. 2021 10h30 HE | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic Diseases of Obesity at the 59th Annual ESPE Meeting

-- New subgroup analysis of Phase 3 data show setmelanotide achieved statistically significant weight loss and hunger reduction compared with placebo at 14 weeks in patients with Bardet-Biedl syndrome...
21 sept. 2021 19h57 HE | Source: Rhythm Pharmaceuticals, Inc.

CORRECTION: Rhythm Pharmaceuticals, Inc.

BOSTON, Sept. 21, 2021 (GLOBE NEWSWIRE) -- In a release issued on Wednesday, September 21 by Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), please note that the symbol ▼ was erroneously omitted from...
21 sept. 2021 18h15 HE | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain

– IMCIVREE is indicated for treatment of obesity and control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or...
20 sept. 2021 07h30 HE | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (setmelanotide) for the treatment of obesity and control of hunger in Bardet-Biedl and Alström Syndromes

BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare...

Page précédente

Page suivante